BROMOCRIPTINE - is an ergoline derivative and dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease (PD), hyperprolactinaemia, neuroleptic malignant syndrome, and type 2 diabetes. Bromocriptine is unique in that it does not have a specific receptor that mediates its action on glucose and lipid metabolism. Rather, its effects are mediated via resetting of dopaminergic and sympathetic tone within the CNS.

USES

• Pituitary Tumors.
• Parkinson's Disease.
• Aacromegaly.
• Infertility.
• Hypogonadism.

GUARANTEE & EXPIRY DATE
100% original from Russian pharmaceutical company Ozon.
All packs are air tight sealed and expire up to 01.2025.
Photos of the product are for illustation purpose only and may vary according to the manufacturer.

DESCRIPTION
Bromocriptine (Parlodel) is used to treat symptoms of hyperprolactinemia (high levels of a natural substance called prolactin in the body) including lack of menstrual periods, discharge from the nipples, infertility (difficulty becoming pregnant) and hypogonadism (low levels of certain natural substances needed for normal development and sexual function). Bromocriptine may be used to treat hyperprolactinemia caused by certain types of tumors that produce prolactin, and may shrink these tumors. Bromocriptine is also used alone or with other treatments to treat acromegaly (condition in which there is too much growth hormone in the body) and Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance). Bromocriptine is used with a diet and exercise program and sometimes with other medications to control blood sugar levels in people with type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Bromocriptine is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). Bromocriptine is in a class of medications called dopamine receptor agonists. It treats hyperprolactinemia by decreasing the amount of prolactin in the body. It treats acromegaly by decreasing the amount of growth hormone in the body. It treats Parkinson's disease by stimulating the nerves that control movement. The way bromocriptine works to treat diabetes is not known.

PACKAGING
BROMOCRIPTINET comes in the form of tablets for oral use: 2.5 mg per tablet, 30 tablets per pack.

Active ingredient:
Bromocriptine Mesylate - 2.87 mg.

Excipients:
Lactose monohydrate 55.63 mg, microcrystalline cellulose 20 mg, potato starch 15 mg, carboxy methyl starch sodium 2 mg, povidone (polyvinylpyropidone) 3.5 mg, magnesium stearate 1 mg.

DOSAGE
Orally with food. Maximum daily dose - 100 mg.

Menstrual irregularities and female infertility: 1.25 mg 2-3 times a day; if the effect is insufficient, the dose is gradually increased to 5-7.5 mg a day (frequency of administration 2-3 times a day). Treatment is continued until the menstrual cycle is normalized and/or ovulation is restored. If necessary, to prevent relapse, treatment can be continued for several cycles.

Premenstrual syndrome: treatment begins on the 14th day of the cycle with 1.25 mg a day. Gradually increase the dose by 1.25 mg a day to 5 mg a day (before menstruation).

Hyperprolactinemia in men: 1.25 mg 2-3 times a day, gradually increasing the dose to 5-10 mg a day.

Prolactinomas: 1.25 mg 2-3 times a day, with a gradual increase in dose to several tablets per day, necessary to maintain an adequate decrease in plasma prolactin concentration.

Acromegaly: the initial dose is 1.25 mg 2-3 times a day, in the future, depending on the clinical effect and side effects, the daily dose is gradually increased to 10-20 mg.

Suppression of lactation: on day 1, 1.25 mg is prescribed 2 times (with meals at breakfast and dinner), then for 14 days, 2.5 mg 2 times a day. To prevent the onset of lactation, the drug should be started several hours after birth or abortion (after stabilization of vital functions). 2-3 days after discontinuation of the drug, insignificant secretion of milk sometimes occurs. It can be eliminated by resuming the drug in the same dose for another 1 week.

Postpartum engorgement of the mammary glands: prescribed once in a dose of 2.5 mg, after 6-12 hours, if necessary, repeat the reception (this is not accompanied by undesirable suppression of lactation).

Beginning postpartum mastitis: the dosage regimen is the same as in the case of suppression of lactation. If necessary, add an antibiotic to the treatment.

Benign diseases of the mammary glands: 1.25 mg 2-3 times a day. The daily dose is gradually increased to 5-7.5 mg.

Parkinson's disease: to ensure optimal tolerance, treatment should be started with the use of a small dose of the drug: 1.25 mg once a day (preferably in the evening) for 1 week. The daily dose of the drug is increased gradually, every week by 1.25 mg, the daily dose is divided into 2-3 doses. An adequate therapeutic result can be achieved within 6-8 weeks of treatment. If this does not happen, the daily dose can be increased further - every week by 2.5 mg / day. The average therapeutic dose of bromocriptine for mono - or combination therapy is 10-30 mg / day. The maximum daily dose is 30 mg. If side effects occur during dose selection, the daily dose should be reduced and maintained at a lower level for at least 1 week. If side effects disappear, the dose can be increased again. Patients with motor impairment noted with levodopa are advised to reduce the dose of levodopa before using bromocriptine. After achieving a satisfactory effect, a further gradual reduction in the dose of levodopa can be undertaken. In some patients, a complete abolition of levodopa is possible.

PRECAUTIONS

• Hypersensitivity to bromocriptine.
• Gestosis.
• Arterial hypertension in the postpartum period.
• Diseases of the cardiovascular system (including arterial hypertension, hypotension).
• Psychoses.
• Liver failure .
• Gottington's chorea.
• Gastrointestinal ulcerative lesions.
• Do not give to children.
• Pregnancy and lactation.

SIDE EFFECTS
Digestive system: nausea, vomiting, dry mouth, constipation, diarrhea, impaired liver function.
Ccentral nervous system: dizziness (usually occur in the first week of treatment), headache, drowsiness, psychomotor agitation, dyskinesia, decreased visual acuity, hallucinations.
Cardiovascular system: orthostatic hypotension, arrhythmia; in some cases, with prolonged use - Raynaud's syndrome (especially in predisposed patients).
Allergic reactions: skin rash.
Other: nasal congestion, cramps in the calf muscles.

STORAGE
Store in dry place at room temperature. Do not exceed storage temperature higher than 25 degrees Celcius. Keep away from direct sunlight. Keep locked and away from children.

QUESTIONS?
Ask us any questions about BROMOCRIPTINET.